CN1263867C - 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法 - Google Patents

用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法 Download PDF

Info

Publication number
CN1263867C
CN1263867C CNB971929327A CN97192932A CN1263867C CN 1263867 C CN1263867 C CN 1263867C CN B971929327 A CNB971929327 A CN B971929327A CN 97192932 A CN97192932 A CN 97192932A CN 1263867 C CN1263867 C CN 1263867C
Authority
CN
China
Prior art keywords
resistance test
patient
host cell
gene
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971929327A
Other languages
English (en)
Chinese (zh)
Other versions
CN1213407A (zh
Inventor
丹尼尔·J·卡彭
克里斯托·约翰·彼得罗普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of CN1213407A publication Critical patent/CN1213407A/zh
Application granted granted Critical
Publication of CN1263867C publication Critical patent/CN1263867C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB971929327A 1996-01-29 1997-01-29 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法 Expired - Fee Related CN1263867C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59300996A 1996-01-29 1996-01-29
US08/593,009 1996-01-29

Publications (2)

Publication Number Publication Date
CN1213407A CN1213407A (zh) 1999-04-07
CN1263867C true CN1263867C (zh) 2006-07-12

Family

ID=24372979

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971929327A Expired - Fee Related CN1263867C (zh) 1996-01-29 1997-01-29 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法

Country Status (18)

Country Link
EP (2) EP0852626B1 (enExample)
JP (1) JP4183749B2 (enExample)
KR (1) KR100537153B1 (enExample)
CN (1) CN1263867C (enExample)
AP (1) AP9801360A0 (enExample)
AT (1) ATE447621T1 (enExample)
AU (1) AU732255B2 (enExample)
CA (1) CA2216126C (enExample)
DE (2) DE69739645D1 (enExample)
EA (1) EA005426B1 (enExample)
ES (1) ES2175355T3 (enExample)
HU (1) HUP9900388A3 (enExample)
IL (1) IL125464A (enExample)
NO (1) NO983421L (enExample)
NZ (1) NZ331376A (enExample)
PL (1) PL328068A1 (enExample)
RO (1) RO118887B1 (enExample)
WO (1) WO1997027319A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109722465A (zh) * 2019-01-07 2019-05-07 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) 一种hiv耐药检测载体和构建方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0810209T3 (da) 1992-08-25 2002-08-12 Monsanto Co Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
DE69712731T2 (de) 1996-01-26 2003-02-06 Virco N.V., Mechelen Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
JP2001512036A (ja) * 1997-07-30 2001-08-21 バイアラジック・インコーポレーテッド 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法
AU3474499A (en) * 1998-04-07 1999-10-25 Southern Research Institute High-throughput method for screening for antiviral activity
CA2329140A1 (en) * 1998-05-26 1999-12-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
DE69924118T2 (de) * 1998-06-19 2005-12-22 The Government of the United States of America, as represented by the Secretary Centers for Disease and Prevention, Office of Technology Verfahren und reagentiensatz zur erkennung von antiviralen wirkstoff resistenzen
US20030148307A1 (en) 1998-06-19 2003-08-07 Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention Method and kit for detecting resistance to antiviral drugs
US6787126B1 (en) 1998-06-19 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Method and kit for detecting resistance to antiviral drugs
CN1154747C (zh) * 1998-06-24 2004-06-23 病毒科学公司 监控核苷类逆转录酶抑制剂抗逆转录病毒治疗和在治疗hiv/aids中指导治疗决定的途径与方法
AU783235B2 (en) 1999-05-28 2005-10-06 Virco Bvba New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
AU2001290911A1 (en) * 2000-09-15 2002-03-26 Virologic, Inc. Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
JP4264256B2 (ja) * 2000-10-20 2009-05-13 ビルコ・ビーブイビーエイ 治療に対する耐性を予測するための生物学的カット−オフ値の確立
AU2631602A (en) 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7247439B1 (en) 2001-06-04 2007-07-24 Monogram Biosciences, Inc. Method of evaluating a patient antibody response to envelope proteins of a virus
US7097970B2 (en) 2001-06-04 2006-08-29 Monogram Biosciences, Inc. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
JP2005513420A (ja) 2001-11-08 2005-05-12 テイボテク・フアーマシユーチカルズ・リミテツド 治療薬をモニタリングするためのプロテアーゼアッセイ
US7217506B2 (en) 2002-07-01 2007-05-15 Tibotec Pharmaceuticals, Ltd. Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistance
WO2004003223A2 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
DE20218008U1 (de) 2002-11-21 2003-03-06 FESTO AG & Co., 73734 Esslingen Anordnung von mehreren Handhabungsvorrichtungen
US8603736B2 (en) 2004-06-07 2013-12-10 Monogram Biosciences, Inc. Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
WO2006089045A2 (en) 2005-02-18 2006-08-24 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors
US20090215028A1 (en) 2005-02-18 2009-08-27 Ellen Paxinos Methods and Compositions for Determining Anti-HIV Drug Susceptibility and Replication Capacity of HIV
US20090087841A1 (en) 2005-05-27 2009-04-02 Monogram Biosciences, Inc. Methods and compositions for determining resistance of hiv-1 to protease inhibitors
WO2006133266A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods for determining resistance or susceptibility to hiv entry inhibitors
US8071284B2 (en) 2005-06-06 2011-12-06 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs
US8114585B2 (en) 2006-06-13 2012-02-14 Monogram Biosciences, Inc. Method for determining human immunodeficiency virus (HIV) coreceptor utilization by examining gp41 molecular determinants
US8338101B2 (en) * 2007-01-23 2012-12-25 Virco Bvba Method for designing a drug regime for HIV-infected patients
US9581595B2 (en) 2007-02-26 2017-02-28 Laboratory Corporation Of America Holdings Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
US20190183855A1 (en) * 2016-08-10 2019-06-20 Riken Composition for treating hepatitis b, and method for evaluating replication activity of hepatitis b virus
RU2646472C1 (ru) * 2016-10-07 2018-03-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей
CN110382009A (zh) * 2016-12-29 2019-10-25 富荣吉有限责任公司 Retro-HBV和Lenti-HBV的混合载体及构建体
JP7773731B2 (ja) * 2020-06-24 2025-11-20 シァメン・ユニヴァーシティ 薬物スクリーニングモデル及びＨＢＶ ｃｃｃＤＮＡを標的化する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291893A1 (en) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
ATE118247T1 (de) * 1988-09-27 1995-02-15 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält.
HU209835B (en) * 1988-12-07 1994-11-28 Univ Osaka Res Found Method for producing of retrovirus protease, reverse transcriptase and integrase
DK0414475T3 (da) * 1989-08-25 1998-02-09 Chiron Corp Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
AU1923795A (en) * 1994-02-18 1995-09-04 University Of Washington Methods and compositions for screening for anti-aids drugs
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
CA2158977A1 (en) * 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
JP2001512036A (ja) * 1997-07-30 2001-08-21 バイアラジック・インコーポレーテッド 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109722465A (zh) * 2019-01-07 2019-05-07 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) 一种hiv耐药检测载体和构建方法
CN109722465B (zh) * 2019-01-07 2022-02-01 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) 一种hiv耐药检测载体和构建方法

Also Published As

Publication number Publication date
PL328068A1 (en) 1999-01-04
CN1213407A (zh) 1999-04-07
DE69711584D1 (de) 2002-05-08
DE69739645D1 (de) 2009-12-17
AP9801360A0 (en) 1998-12-31
EA005426B1 (ru) 2005-02-24
EP1170380A3 (en) 2003-05-02
NO983421D0 (no) 1998-07-24
AU1952897A (en) 1997-08-20
NZ331376A (en) 2000-03-27
AU732255B2 (en) 2001-04-12
CA2216126C (en) 2009-03-31
ES2175355T3 (es) 2002-11-16
HUP9900388A3 (en) 2005-03-29
KR100537153B1 (ko) 2006-12-15
NO983421L (no) 1998-09-25
JP4183749B2 (ja) 2008-11-19
WO1997027319A1 (en) 1997-07-31
EP1170380A2 (en) 2002-01-09
ATE447621T1 (de) 2009-11-15
IL125464A (en) 2007-12-03
RO118887B1 (ro) 2003-12-30
EP0852626A1 (en) 1998-07-15
KR19990082129A (ko) 1999-11-15
EP1170380B1 (en) 2009-11-04
JP2000503849A (ja) 2000-04-04
IL125464A0 (en) 1999-03-12
EP0852626A4 (en) 1999-08-25
EP0852626B1 (en) 2002-04-03
DE69711584T2 (de) 2002-11-07
CA2216126A1 (en) 1997-07-31
EA199800669A1 (ru) 1999-02-25
HUP9900388A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
CN1263867C (zh) 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法
US6242187B1 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
CN1452661A (zh) 用于监测hiv药物抗性的病毒载体
CN1833024A (zh) 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
CN1836042A (zh) 用于基因沉默的hbv和hcv保守序列
CN1991365A (zh) 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法
CN1117876C (zh) 刺激促生长素抑制素和胰岛素产生的化合物的筛选方法
CN1942585A (zh) 含人丙型肝炎病毒全长基因组的核酸构建物、核酸构建物转入其中的重组全长病毒基因组复制型细胞和生产丙型肝炎病毒颗粒的方法
CN1646706A (zh) 应用重组病毒分析试验评价病毒受体/共受体用途以及病毒侵入抑制剂的组合物和方法
CN1646704A (zh) 确定致病性病毒对蛋白酶抑制剂敏感性的组合物和方法
CN1125467A (zh) 一种对白细胞介素-5受体依赖细胞信息传递通路有调整作用的物质筛选方法
CN1820081A (zh) 分析基因导入位点的方法
CN1545550A (zh) 含泡沫逆转录病毒包膜蛋白的感染性嗜肝dna病毒颗粒的制备及其使用方法
JP2001512036A (ja) 抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法
CN1529758A (zh) 新的表达载体及其应用
CN1886417A (zh) Hiv－依赖型表现构筑体及其用途
US20090176202A1 (en) Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV
HK1019077A (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
CN1969048A (zh) 研究hiv的遗传和功能变异性的方法以及用于该方法的试剂盒
CN1547618A (zh) 利用重组病毒分析法评价病毒受体/辅助受体使用和病毒侵入抑制剂的组合物和方法
CN1446265A (zh) 检测抗反转录病毒治疗的方式与方法和在hiv/aids治疗中的指导治疗方案
CN1292069C (zh) Hiv－1病毒tat－蛋白突变体
AU776535B2 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
CN1827768A (zh) 增强有用基因表达的核酸序列和方法
CN1671729A (zh) 人Corin基因的控制序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1019077

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee